Literature DB >> 9736043

Differential expression and origin of membrane-type 1 and 2 matrix metalloproteinases (MT-MMPs) in association with MMP2 activation in injured human livers.

N Théret1, O Musso, A L'Helgoualc'h, J P Campion, B Clément.   

Abstract

Matrix metalloproteinase-2 (MMP2) activation is associated with basement membrane remodeling that occurs in injured tissues and during tumor invasion. The newly described membrane-type MMPs (MT-MMPs) form a family of potential MMP2 activators. We investigated the localization and steady-state levels of MT1-MMP and MT2-MMP mRNA, compared with those of MMP2 and tissue inhibitor of MMP-2 in 22 hepatocellular carcinomas, 12 liver metastases from colonic adenocarcinomas, 13 nontumoral samples from livers with metastases, 10 benign tumors, and 6 normal livers. MMP2 activation was analyzed by zymography in the same series. The expression of MT1-MMP mRNA and the activation of MMP-2 were increased in hepatocellular carcinomas, metastases, and cholestatic nontumoral samples. MT2-MMP mRNA was rather stable in the different groups. MT1-MMP mRNA levels, but not MT2-MMP mRNA, correlated with MMP-2 and tissue inhibitor of MMP-2 mRNA levels and with MMP2 activation. In situ hybridization showed that MT1-MMP mRNA was expressed in stromal cells, and MT2-MMP mRNA was principally located in both hepatocytes and biliary epithelial cells. Consistently, freshly isolated hepatocytes expressed only MT2-MMP mRNA, and culture-activated hepatic stellate cells showed high levels of MT1-MMP mRNA. These results indicate that in injured livers, MMP2 activation is related to a coordinated high expression of MMP2, tissue inhibitor of MMP-2, and MT1-MMP. Furthermore, the finding of a preferential expression of MT2-MMP in hepatocytes, together with our previous demonstration that the activation of stellate cell-derived MMP2 in co-culture requires interactions with hepatocytes (Am J Pathol 1997, 150:51-58), suggests that parenchymal cells might play a pivotal role in the MMP2 activation process.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9736043      PMCID: PMC1853032          DOI: 10.1016/S0002-9440(10)65636-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase.

Authors:  H P Emonard; A G Remacle; A C Noël; J A Grimaud; W G Stetler-Stevenson; J M Foidart
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

2.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

3.  Cloning of a human gene potentially encoding a novel matrix metalloproteinase having a C-terminal transmembrane domain.

Authors:  T Takino; H Sato; E Yamamoto; M Seiki
Journal:  Gene       Date:  1995-04-03       Impact factor: 3.688

Review 4.  Tumor cell interactions with the extracellular matrix during invasion and metastasis.

Authors:  W G Stetler-Stevenson; S Aznavoorian; L A Liotta
Journal:  Annu Rev Cell Biol       Date:  1993

5.  Cooperation of Ito cells and hepatocytes in the deposition of an extracellular matrix in vitro.

Authors:  O Loréal; F Levavasseur; C Fromaget; D Gros; A Guillouzo; B Clément
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats.

Authors:  T Takahara; K Furui; J Funaki; Y Nakayama; H Itoh; C Miyabayashi; H Sato; M Seiki; A Ooshima; A Watanabe
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

7.  Expression of membrane-type matrix metalloproteinase in human gastric carcinomas.

Authors:  H Nomura; H Sato; M Seiki; M Mai; Y Okada
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

8.  Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver.

Authors:  S Milani; H Herbst; D Schuppan; C Grappone; G Pellegrini; M Pinzani; A Casini; A Calabró; G Ciancio; F Stefanini
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

9.  A matrix metalloproteinase expressed on the surface of invasive tumour cells.

Authors:  H Sato; T Takino; Y Okada; J Cao; A Shinagawa; E Yamamoto; M Seiki
Journal:  Nature       Date:  1994-07-07       Impact factor: 49.962

10.  A plasma membrane-associated component of ovarian adenocarcinoma cells enhances the catalytic efficiency of matrix metalloproteinase-2.

Authors:  T N Young; S V Pizzo; M S Stack
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

View more
  9 in total

1.  Collagen type IV, laminin, alpha-smooth muscle actin (alphaSMA), alpha1 and alpha6 integrins expression in the liver with metastases from malignant gastrointestinal tumours.

Authors:  Maya Vladova Gulubova
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

2.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

3.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

4.  Prokineticin 2/Bv8 is expressed in Kupffer cells in liver and is down regulated in human hepatocellular carcinoma.

Authors:  Justin Monnier; Claire Piquet-Pellorce; Jean-Jacques Feige; Orlando Musso; Bruno Clement; Bruno Turlin; Nathalie Theret; Michel Samson
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

5.  Hepatoprotective effect of MMP-19 deficiency in a mouse model of chronic liver fibrosis.

Authors:  Marketa Jirouskova; Olga Zbodakova; Martin Gregor; Karel Chalupsky; Lenka Sarnova; Marian Hajduch; Jiri Ehrmann; Marie Jirkovska; Radislav Sedlacek
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

6.  MMP-15 is upregulated in preeclampsia, but does not cleave endoglin to produce soluble endoglin.

Authors:  Tu'uhevaha J Kaitu'u-Lino; Kirsten Palmer; Laura Tuohey; Louie Ye; Stephen Tong
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  TIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis.

Authors:  Cristina Valacca; Evelyne Tassone; Paolo Mignatti
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

8.  Identification of biomarkers for hepatocellular carcinoma using network-based bioinformatics methods.

Authors:  Lingyan Zhang; Ying Guo; Bibo Li; Juan Qu; Chunbao Zang; Fang Li; Ying Wang; Hua Pang; Shaolin Li; Qingjun Liu
Journal:  Eur J Med Res       Date:  2013-10-01       Impact factor: 2.175

9.  Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of Metalloproteinase (TIMPs).

Authors:  Isao Okazaki; Takuji Noro; Nobuhiro Tsutsui; Eigoro Yamanouchi; Hajime Kuroda; Masayuki Nakano; Hiroaki Yokomori; Yutaka Inagaki
Journal:  Cancers (Basel)       Date:  2014-06-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.